BioSpace News Archive

According to the global Nuclear Medicine market size was estimated at USD 9.50 billion in 2021 and is expected to surpass around USD 25.40 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.

According to Nova one advisor, the global In Vitro Fertilization /IVF market was valued at USD 638 million in 2021 and it is expected to hit around USD 2.4 billion by 2030 with a CAGR of 14.9% during the forecast period 2022 to 2030.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of the American Medical Association (JAMA) published positive results from two pivotal Phase 3 studies (DERMIS-1 and DERMIS-2) evaluating roflumilast cream 0.3% as a once daily, topical treatment for chronic plaque psoriasis.

Gettysburg Cancer Center, a leading community oncology practice in Pennsylvania for three decades, unveiled a new name and logo as part of an extensive rebrand and opened their new clinic at 6475 Carlisle Pike, Mechanicsburg, where the practice’s founder and medical director, Satish Shah, MD, and Jasmine Ross, MD are treating patients.

Invenra announced that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.

ExThera Medical is pleased to announce that published data from a preliminary European study demonstrating in vitro adsorption of human circulating tumor cells (CTC) has been corroborated at a major US cancer center.

HAVN Life Sciences Inc. announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.

In May 2022, FDA Commissioner Robert M. Califf, M.D., asked that I conduct an internal agency review of the agency’s actions related to multiple reports of Cronobacter illness in infants, the Abbott’s infant formula manufacturing plant in Sturgis, Michigan, and confounding issues that led to a shortage of infant formulas.

OraSure Technologies, Inc. announced that the Company has been selected to provide its OraQuick® In-Home HIV tests in support of the Centers for Disease Control and Preventions “Together Take Me Home,” HIV self-test program.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A.